Crinetics Pharmaceuticals, Inc.CRNXNASDAQ
LOADING
|||
EV to Sales: Premium Valuation
Trending higher, above historical average, strong compound growth.
Left:
||||
Enterprise value to sales ratio
Latest
3770.56
↑ 197% above average
Average (8y)
1270.30
Historical baseline
Range
High:4796.45
Low:131.45
CAGR
+27.0%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 3770.56 | +633.5% |
| 2023 | 514.08 | +164.2% |
| 2022 | 194.57 | -76.5% |
| 2021 | 829.63 | -82.7% |
| 2020 | 4796.45 | +900.7% |
| 2019 | 479.29 | +264.6% |
| 2018 | 131.45 | -17.5% |
| 2017 | 159.39 | -71.4% |
| 2016 | 557.24 | - |